About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

U.S. Biopharmaceuticals Market

U.S. Biopharmaceuticals Market Unlocking Growth Potential: Analysis and Forecasts 2025-2033

U.S. Biopharmaceuticals Market by Type (Immunomodulators {Monoclonal Antibodies, Cytokines, Others}, Enzymes {Hydrolases, Lyases, Others}, Vaccines {Recombinant Vaccines/Conjugate/Subunit, Inactivated, Live Attenuated, Toxoid}, Hormones {Human Growth Hormones, Insulin, Others}, Others), by Application (Cardiology, Oncology, Respiratory, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies), by Forecast 2026-2034

Feb 10 2025

Base Year: 2025

180 Pages

U.S. Biopharmaceuticals Market Unlocking Growth Potential: Analysis and Forecasts 2025-2033

Key Insights

The U.S. Biopharmaceuticals Market size was valued at USD 846.72 USD Billion in 2023 and is projected to reach USD 1285.79 USD Billion by 2032, exhibiting a CAGR of 8.5 % during the forecast period. The US biopharmaceutical industry provides the backbone of innovation in the healthcare systems; the industry focuses on developing therapeutic products sourced from biological products. This largely comprises products such as monoclonal antibodies, vaccines, gene therapies, and recombinant proteins among others. These biologics are sharply different from simple small-molecule drugs which target various diseases with high efficiency, and often with better results. Biopharmaceuticals demonstrate versatility in their therapeutic applications across several disease management areas including oncology and immunology to meet medical demands and enhance patient experience. Some of the attributes of biopharmaceuticals include their selectivity hence reducing the blocking of other proteins which can lead to severe side effects as well as their non-immunogenicity. Further, their manufacturing methods, and the use of living organisms, provide the benefits of scalability and differentiation, always enabling a quick response to the emergence of new threats to people’s health. The advantages, outlined in the literature, cover more than the well-being of single recipients and have led to the progression of personalized medicine as a medical approach; more importantly, they have also spurred economic development from an innovative standpoint, creating employment opportunities.

U.S. Biopharmaceuticals Market Trends

Accelerating Prevalence of Chronic Conditions: The escalating incidence of cancer, cardiovascular diseases, and diabetes fuels the demand for advanced treatments offered in the biopharmaceutical market.
Precision Medicine Revolution: Technological advancements in genetic sequencing empower the development of personalized therapies targeting unique genetic variations, propelling the adoption of precision medicine approaches.
Biotechnological Breakthroughs: Continuous innovations in protein engineering, gene editing, and RNA therapeutics accelerate innovation and enhance therapeutic efficacy.
Digitalization and AI Integration: The convergence of digital health and artificial intelligence (AI) optimizes drug discovery, clinical trials, and precision medicine, fostering greater efficiency and personalized treatments.
Shift Towards Value-Based Care: Governments and healthcare providers increasingly prioritize value-based pricing models, driving the development of cost-effective and patient-centric therapies.

U.S. Biopharmaceuticals Market Market Size and Forecast (2024-2030) — U.S. Biopharmaceuticals Market Company Market Share

Driving Forces: What's Propelling the U.S. Biopharmaceuticals Market

Increasing healthcare expenditure
Government initiatives and support for R&D
Patent expiries of blockbuster drugs

Challenges and Restraints in the U.S. Biopharmaceuticals Market

High drug development costs
Regulatory challenges
Reimbursement issues

Emerging Trends in U.S. Biopharmaceuticals

Precision medicine and personalized therapies
Artificial intelligence and machine learning
Digital health and telehealth

Growth Catalysts in the U.S. Biopharmaceuticals Industry

Strategic mergers and acquisitions
Partnerships and collaborations
Expansion into emerging markets

Market Segmentation: U.S. Biopharmaceuticals Analysis

Type

Immunomodulators
Enzymes
Vaccines
Hormones
Others

Application

Cardiology
Oncology
Respiratory
Others

Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

Leading Players in the U.S. Biopharmaceuticals Market

Significant Developments in U.S. Biopharmaceuticals Sector

September 2023: Amgen Inc.'s acquisition of Horizon Therapeutics is expected to strengthen its position in the rare disease market, expanding its treatment options for patients worldwide.
August 2023: Pfizer Inc. obtained FDA approval for ELREXFIO, a targeted therapy for Relapsed or Refractory Multiple Myeloma, demonstrating the company's commitment to innovative cancer treatments.
July 2023: AstraZeneca and Sanofi's Beyfortus gained FDA approval for preventing RSV and LRTD in newborns and infants, underscoring the advancement of preventive therapies within the biopharmaceuticals sector.
June 2023: AbbVie Inc. and Allergan combined to form AbbVie, creating a leading player in the global biopharmaceuticals industry, with a broad portfolio of therapies and a commitment to driving innovation.
May 2023: The U.S. FDA granted breakthrough therapy designation to Moderna's personalized cancer vaccine, mRNA-4157, recognizing its potential to revolutionize individualized cancer treatments.

Comprehensive Coverage U.S. Biopharmaceuticals Market Report

The report provides a comprehensive analysis of the U.S. biopharmaceuticals market, including:

Market Overview
Market trends
Market size and projections
Segmentation analysis
Regional analysis
Competitive landscape
Industry Outlook

Regional Insight

The U.S. biopharmaceuticals market is segmented into five regions:

Northeast
Midwest
South
West
Mountain

U.S. Biopharmaceuticals Market Market Share by Region - Global Geographic Distribution — U.S. Biopharmaceuticals Market Regional Market Share

DROCT

Drivers: Growing prevalence of chronic diseases, increasing healthcare expenditure, advancements in biotechnology and genetic engineering
Restraints: High drug development costs, regulatory challenges, reimbursement issues
Opportunities: Precision medicine and personalized therapies, artificial intelligence and machine learning, expansion into emerging markets
Challenges: Patent expiries of blockbuster drugs, reimbursement pressures
Threats: Generic competition, technological disruption

Pricing Analysis

The prices of biopharmaceutical products vary widely depending on the type of drug, its indication, and the manufacturer. The prices are also influenced by factors such as the cost of research and development, manufacturing costs, and marketing expenses.

Import And Export Analysis

The U.S. is a major importer and exporter of biopharmaceutical products. The U.S. exports biopharmaceuticals to countries all over the world, including Europe, Asia, and Latin America. The U.S. also imports biopharmaceuticals from countries such as China, India, and Mexico.

Segmentation

The U.S. biopharmaceuticals market is segmented by type, application, and distribution channel. The type segment includes immunomodulators, enzymes, vaccines, hormones, and others. The application segment includes cardiology, oncology, respiratory, and others. The distribution channel segment includes hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

Patent/Trademark Analysis

The U.S. biopharmaceuticals market is highly patent-protected. Patents are used to protect the intellectual property of biopharmaceutical manufacturers. Trademarks are used to protect the brand names of biopharmaceutical products.

Geographic Coverage of U.S. Biopharmaceuticals Market

Higher Coverage

Lower Coverage

No Coverage

U.S. Biopharmaceuticals Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 8.5 % % from 2020-2034
Segmentation	By Type Immunomodulators {Monoclonal Antibodies Cytokines Others} Enzymes {Hydrolases Lyases Others} Vaccines {Recombinant Vaccines/Conjugate/Subunit Inactivated Live Attenuated Toxoid} Hormones {Human Growth Hormones Insulin Others} Others By Application Cardiology Oncology Respiratory Others By Distribution Channel Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies By Geography

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. Rising Prevalence of Chronic Diseases to Drive Demand for Biopharmaceuticals
- - 3.3. Market Restrains
  - - 3.3.1. Availability of Drugs at High-Cost May Limit Market Growth
- - 3.4. Market Trends
  - - 3.4.1. Growing Emphasis on Monoclonal Antibody-based Therapeutics
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. U.S. Biopharmaceuticals Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Type
  - 5.1.1. Immunomodulators {Monoclonal Antibodies
  - 5.1.2. Cytokines
  - 5.1.3. Others}
  - 5.1.4. Enzymes {Hydrolases
  - 5.1.5. Lyases
  - 5.1.6. Others}
  - 5.1.7. Vaccines {Recombinant Vaccines/Conjugate/Subunit
  - 5.1.8. Inactivated
  - 5.1.9. Live Attenuated
  - 5.1.10. Toxoid}
  - 5.1.11. Hormones {Human Growth Hormones
  - 5.1.12. Insulin
  - 5.1.13. Others}
  - 5.1.14. Others
- 5.2. Market Analysis, Insights and Forecast - by Application
  - 5.2.1. Cardiology
  - 5.2.2. Oncology
  - 5.2.3. Respiratory
  - 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - by Distribution Channel
  - 5.3.1. Hospital Pharmacies
  - 5.3.2. Drug Stores & Retail Pharmacies
  - 5.3.3. Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast - by Region
  - 5.4.1.
6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 Pfizer Inc. (U.S.)
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 AbbVie Inc. (U.S.)
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 Bristol-Myers Squibb Company (U.S.)
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Johnson & Johnson Services Inc. (U.S.)
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 Bayer AG (Germany)
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 Lilly (U.S.)
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 Sanofi (France)
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 Merck & Co. Inc. (U.S.)
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)
    - 6.2.9 F. Hoffmann-La Roche Ltd. (Switzerland)
      6.2.9.1. Overview
      6.2.9.2. Products
      6.2.9.3. SWOT Analysis
      6.2.9.4. Recent Developments
      6.2.9.5. Financials (Based on Availability)
    - 6.2.10 Novartis AG (Switzerland)
      6.2.10.1. Overview
      6.2.10.2. Products
      6.2.10.3. SWOT Analysis
      6.2.10.4. Recent Developments
      6.2.10.5. Financials (Based on Availability)
    - 6.2.11 GSK plc (U.K.)
      6.2.11.1. Overview
      6.2.11.2. Products
      6.2.11.3. SWOT Analysis
      6.2.11.4. Recent Developments
      6.2.11.5. Financials (Based on Availability)
    - 6.2.12 Takeda Pharmaceutical Company Limited. (Japan)
      6.2.12.1. Overview
      6.2.12.2. Products
      6.2.12.3. SWOT Analysis
      6.2.12.4. Recent Developments
      6.2.12.5. Financials (Based on Availability)

List of Figures

Figure 1: U.S. Biopharmaceuticals Market Revenue Breakdown (USD Billion, %) by Product 2025 & 2033
Figure 2: U.S. Biopharmaceuticals Market Share (%) by Company 2025

List of Tables

Table 1: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Type 2020 & 2033
Table 2: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Type 2020 & 2033
Table 3: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Application 2020 & 2033
Table 4: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Application 2020 & 2033
Table 5: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 6: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Distribution Channel 2020 & 2033
Table 7: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Region 2020 & 2033
Table 8: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Region 2020 & 2033
Table 9: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Type 2020 & 2033
Table 10: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Type 2020 & 2033
Table 11: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Application 2020 & 2033
Table 12: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Application 2020 & 2033
Table 13: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 14: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Distribution Channel 2020 & 2033
Table 15: U.S. Biopharmaceuticals Market Revenue USD Billion Forecast, by Country 2020 & 2033
Table 16: U.S. Biopharmaceuticals Market Volume K Units Forecast, by Country 2020 & 2033

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Biopharmaceuticals Market?

The projected CAGR is approximately 8.5 % %.

2. Which companies are prominent players in the U.S. Biopharmaceuticals Market?

Key companies in the market include Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Lilly (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), GSK plc (U.K.), Takeda Pharmaceutical Company Limited. (Japan).

3. What are the main segments of the U.S. Biopharmaceuticals Market?

The market segments include Type, Application, Distribution Channel.

4. Can you provide details about the market size?

The market size is estimated to be USD 1285.79 USD Billion as of 2022.

5. What are some drivers contributing to market growth?

Rising Prevalence of Chronic Diseases to Drive Demand for Biopharmaceuticals.

6. What are the notable trends driving market growth?

Growing Emphasis on Monoclonal Antibody-based Therapeutics.

7. Are there any restraints impacting market growth?

Availability of Drugs at High-Cost May Limit Market Growth.

8. Can you provide examples of recent developments in the market?

September 2023 – Amgen Inc. is anticipated to acquire Horizon Therapeutics by the fourth quarter of 2023 with an intention to serve patients around the world suffering from rare diseases.

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in USD Billion and volume, measured in K Units.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "U.S. Biopharmaceuticals Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the U.S. Biopharmaceuticals Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the U.S. Biopharmaceuticals Market?

To stay informed about further developments, trends, and reports in the U.S. Biopharmaceuticals Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Get Free Sample

Pre Order Enquiry Request discount

Pricing

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Ask for customization

The response was good, and I got what I was looking for as far as the report. Thank you for that.

Erik Perison

US TPS Business Development Manager at Thermon

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

Shankar Godavarti

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you againg for a good quality report